Background: Early detection of cognitive decline, including mild cognitive impairment, is expected to provide a better prognosis. Several studies have suggested an association between periodontitis and mild cognitive impairment.
Objectives/design: To test the hypothesis that there is an association between severe periodontitis and mild cognitive impairment in community residents who participated in a dental health check-up program.
Participants/setting: Community residents who participated in our dental health checkup program were enrolled (age=67.5±9.9, 62.9% female).
Measurements: Mild cognitive impairment was tested using the MCI screening test. Periodontitis was diagnosed based on a widely used clinical periodontal parameter, the probing pocket depth. Statistical analysis was based on logistic regression models adjusted for potential confounders.
Results: Among 321 subjects, mild cognitive impairment was detected in 41. Severe periodontitis (probing pocket depth > 6mm) was detected in 123 cases, with a higher prevalence of mild cognitive impairment in the severe periodontitis group (65.9%) than in the unimpaired group (34.3%). The inclusion of four variables (age, education, functional teeth, and presence of severe periodontitis) in a multivariate logistic regression model revealed a statistically significant difference in the association between severe periodontitis and mild cognitive impairment (odds ratio = 4.024, p < 0.001).
Conclusions: A strong association was seen between severe periodontitis and mild cognitive impairment. Severe periodontitis appears to be a risk factor for mild cognitive impairment, and patients with severe periodontitis should be assessed for mild cognitive impairment.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11622601 | PMC |
http://dx.doi.org/10.14283/jarlife.2024.16 | DOI Listing |
Metab Brain Dis
January 2025
Department of Biological Sciences (Pharmacology and Toxicology), National Institute of Pharmaceutical Education and Research (NIPER) Hyderabad, Balanagar, Hyderabad, 500037, Telangana, India.
The negative impact of repeated-mild traumatic brain injury (rmTBI) is profoundly seen in circadian-disrupted individuals. The unrelenting inflammation, glial activation, and gut dysbiosis are key neuropathological aberrations in the aftermath of rmTBI. In this study, we examined the impact of chitosan lactate (CL) on circadian disturbance (CD) + rmTBI-generated neurological dysfunctions and its prebiotic response on the gut-brain axis.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
1st Department of Neurology, Aiginition Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece.
Background: Numerous studies have highlighted the role of oxidative stress in Alzheimer's disease (AD) development. Yet, the alignment of systemic and central oxidative stress biomarkers is unclear across diverse populations in the AD continuum. This study aims to assess protein damage levels in plasma and cerebrospinal fluid (CSF) within the AD continuum.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chong Qing, China.
Background: Alzheimer's disease (AD) frequently coexists with cerebral small vessel disease (CSVD) is common in the aging population, yet the underlying mechanisms are not yet fully understood. Both long-term blood pressure variability (BPV) and plasma neurofilament light (PNFL) were identified as potential biomarkers for AD and CSVD. This study aims to understand the mechanisms of comorbidity between AD and CSVD by investigating the associations among BPV, PNFL, and comorbidity.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
College of Public Health, University of Kentucky, Lexington, KY, USA.
Background: Brain arteriolosclerosis (B-ASC) is a pathologic hallmark characterized by dysmorphic brain arteriolar wall thickening. B-ASC is a common finding at autopsy in aged persons - some degree of B-ASC is seen in >80% of brains beyond age 80 years - and is associated with cognitive impairment. Hypertension and diabetes are widely recognized as risk factors for B-ASC.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Rush Alzheimer's Disease Center, Chicago, IL, USA.
Background: The recent approval of two anti-amyloid antibodies, Aducanamab and Lecanamab, have set the stage for the next generation of anti-amyloid treatments. Despite the capability of these treatments to lower Aβ brain levels, there is thus far limited clinical efficacy on cognitive outcomes. Because eligibility for treatment includes individuals with MCI or mild dementia, that often harbor mixed pathologies, the cognitive impact of other brain pathologies may be important.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!